Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Abstract Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end‐stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targe...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-07-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Subjects: | |
Online Access: | https://doi.org/10.1002/edm2.72 |
id |
doaj-b6f31cc5f9034e82bc88e5083c0377f3 |
---|---|
record_format |
Article |
spelling |
doaj-b6f31cc5f9034e82bc88e5083c0377f32020-11-25T00:09:32ZengWileyEndocrinology, Diabetes & Metabolism2398-92382019-07-0123n/an/a10.1002/edm2.72Safety and efficacy of antihyperglycaemic agents in diabetic kidney diseaseSebastian Niezen0Humberto Diaz del Castillo1Lumen A. Mendez Castaner2Alessia Fornoni3School of Medicine Anahuac University Mexico City MexicoSchool of Medicine Universidad Autónoma de Guadalajara Guadalajara MexicoKatz Family Division of Nephrology and Hypertension University of Miami Miami FloridaKatz Family Division of Nephrology and Hypertension University of Miami Miami FloridaAbstract Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end‐stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targets in DKD with agents blocking the renin‐angiotensin system confer superior renoprotection when compared to other agents. However, the effects on renal outcomes of antihyperglycaemic agents in these patients have not been reported or studied broadly until recent years. The intent of this article is to review the available data on safety, efficacy, impact on renal outcomes and pathophysiology implications of the most utilized antihyperglycaemic agents in DKD/ESRD.https://doi.org/10.1002/edm2.72antihyperglycaemic agentchronic kidney diseasediabetic kidney diseaseefficacysafety |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sebastian Niezen Humberto Diaz del Castillo Lumen A. Mendez Castaner Alessia Fornoni |
spellingShingle |
Sebastian Niezen Humberto Diaz del Castillo Lumen A. Mendez Castaner Alessia Fornoni Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease Endocrinology, Diabetes & Metabolism antihyperglycaemic agent chronic kidney disease diabetic kidney disease efficacy safety |
author_facet |
Sebastian Niezen Humberto Diaz del Castillo Lumen A. Mendez Castaner Alessia Fornoni |
author_sort |
Sebastian Niezen |
title |
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease |
title_short |
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease |
title_full |
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease |
title_fullStr |
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease |
title_full_unstemmed |
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease |
title_sort |
safety and efficacy of antihyperglycaemic agents in diabetic kidney disease |
publisher |
Wiley |
series |
Endocrinology, Diabetes & Metabolism |
issn |
2398-9238 |
publishDate |
2019-07-01 |
description |
Abstract Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end‐stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targets in DKD with agents blocking the renin‐angiotensin system confer superior renoprotection when compared to other agents. However, the effects on renal outcomes of antihyperglycaemic agents in these patients have not been reported or studied broadly until recent years. The intent of this article is to review the available data on safety, efficacy, impact on renal outcomes and pathophysiology implications of the most utilized antihyperglycaemic agents in DKD/ESRD. |
topic |
antihyperglycaemic agent chronic kidney disease diabetic kidney disease efficacy safety |
url |
https://doi.org/10.1002/edm2.72 |
work_keys_str_mv |
AT sebastianniezen safetyandefficacyofantihyperglycaemicagentsindiabetickidneydisease AT humbertodiazdelcastillo safetyandefficacyofantihyperglycaemicagentsindiabetickidneydisease AT lumenamendezcastaner safetyandefficacyofantihyperglycaemicagentsindiabetickidneydisease AT alessiafornoni safetyandefficacyofantihyperglycaemicagentsindiabetickidneydisease |
_version_ |
1725411499578490880 |